Masitinib combined with standard gemcitabine chemotherapy: In vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model

PLoS ONE

Volumn 5, Issue 3, 2010, Pages

  Humbert, Martine ^a   Castéran, Nathalie ^a   Letard, Sébastien ^b,c,d   Hanssens, Katia ^a   Iovanna, Juan ^e   Finetti, Pascal ^c,d   Bertucci, François ^c,d   Bader, Thomas ^a   Mansfield, Colin D ^a   Moussy, Alain ^a   Hermine, Olivier ^f   Dubreuil, Patrice ^b,c,d  

^a AB Science   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

^e INSERM   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FOCAL ADHESION KINASE; GEMCITABINE; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; MASITINIB; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR AB; PROTEIN KINASE LYN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; UNCLASSIFIED DRUG; WNT PROTEIN; DEOXYCYTIDINE; DRUG DERIVATIVE; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS TUMOR; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; ANIMAL; DISEASE MODEL; GENE EXPRESSION REGULATION; METABOLISM; MOUSE MUTANT; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MICE; MICE, SCID; PANCREATIC NEOPLASMS; THIAZOLES;

EID: 77950128955     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009430     Document Type: Article

References (30)

1. Li D, Xie K, Wolff R, Abbruzzese JL (2004) Pancreatic cancer. The Lancet 363: 1049-1057.
2. Sultana A, Tudur Smith C, Cunningham D, Starling N, Tait D, et al. (2007) Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 96: 1183-1190.
3. Burris HA, 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, et al. (1997) Improvements in survival and clinical benefit with gemcitabine as firstline therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413.
4. Saif MW (2006) Pancreatic cancer: Highlights from the 42nd annual meeting of the American Society of Clinical Oncology. JOP 7: 337-348.
5. Sultana A, Ghaneh P, Cunningham D, Starling N, Neoptolemos JP, et al. (2008) Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison. BMC Cancer 8: 192. doi:10.1186/1471-2407-8-192.
6. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, et al. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966.
7. Ozawa F, Friess H, Tempia-Calierav A, Kleeff J, Büchler MW (2001) Growth Factors and Their Receptors in Pancreatic Cancer. Teratogenesis Carcinog. Mutagen 21: 27-44.
8. Duxbury MS, Ito H, Benoit E, Zinner MJ, Ashley SW, et al. (2003) RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem Biophys Res Commun 311: 786-792.
9. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE, et al. (2004) siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity. J Am Coll Surg 198: 953-959.
10. Summy JM, Gallick GE (2003) Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22: 337-358.
11. Yeatman TJ (2004) A renaissance for SRC. Nat Rev Cancer 4: 470-480.
12. Esposito I, Menicagli M, Funel N, Bergmann F, Boggi U, et al. (2004) Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J Clin Pathol 57: 630-636.
13. Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, et al. (2007) Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 13: 1211-1218.
14. Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, et al. (2009) Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS ONE 4(9): e7258. doi:10.1371/journal.pone.0007258.
15. Ogilvie G, Hahn KA, Rusk T, Devauchelle P, Leblanc A, et al. (2008) Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 22: 1301-1309.
16. Tebib J, Mariette X, Bourgeois P, Flipo RM, Gaudin P, et al. (2009) Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study. Arthritis Res Ther 11: R95. doi:10.1186/ar2740.
17. Chen J, Rocken C, Nitsche B, Hosius C, Gschaidmeier H, et al. (2006) The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression. Cancer Lett 233: 328-337.
18. Giroux V, Malicet C, Barthet M, Gironella M, Archange C, et al. (2006) p8 is a new target of gemcitabine in pancreatic cancer cells. Clin Cancer Res 12: 235-241.
19. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Mamessier E, et al. (2006) Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 66: 4636-4644.
20. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
21. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95: 14863-14868.
22. Yasuda A, Sawai H, Takahashi H, Ochi N, Matsuo Y, et al. (2006) The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells. Mol Cancer 5: 46. doi:10.1186/1476-4598-5-46.
23. Hammond JR, Lee S, Ferguson PJ (1999) [3H]gemcitabine uptake by nucleoside transporters in a human head and neck squamous carcinoma cell line. J Pharmacol Exp Ther 288: 1185-1191.
24. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324: 1457-1461.
25. Murtaugh LC (2008) The what, where, when and how of Wnt/beta-catenin signaling in pancreas development. Organogenesis 4: 81-86.
26. Hwang RF, Yokoi K, Bucana CD, Tsan R, Killion JJ, et al. (2003) Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 9: 6534-6544.
27. Yokoi K, Sasaki T, Bucana CD, Fan D, Baker CH, et al. (2005) Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. Cancer Res 65: 10371-10380.
28. Trevino JG, Summy JM, Lesslie DP, Parikh NU, Hong DS, et al. (2006) Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol 168: 962-972.
29. Force T, Krause DS, Van Etten RA (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7: 332-344.
30. Hammel P, Mornex F, Deplanque G, Mitry E, Levy P, et al. (2009) Oral tyrosine kinase inhibitor masitinib in combination with gemcitabine in patients with advanced pancreatic cancer: A multicenter phase II study. J Clin Oncol 27: 15s. (suppl; abstr 4617).